Hypothesis

Enterochromaffin (EC) cell senescence acts as a upstream controller that drives the coordinated manifestation of aging hallmarks through a serotonin‑dependent epigenetic reprogramming circuit.

Mechanistic rationale

1. EC‑cell senescence triggers a serotonin‑rich SASP – Senescent EC cells up‑regulate tryptophan hydroxylase 1 (TPH1) and release excess serotonin together with classic SASP factors (IL‑6, IL‑1β, ROS) (claim)[2]. Elevated luminal serotonin activates 5‑HT₄ receptors on enteroendocrine and neuronal cells, increasing cAMP/PKA signaling that phosphorylates DNA methyltransferases (DNMT1/3A) and histone deacetylases (HDAC2) (claim)[5].

2. Epigenetic wave propagates via the gut‑brain axis – Serotonin‑mediated kinase activity alters the epigenetic state of intestinal stem cells (ISCs), biasing them toward a senescent‑like transcriptional profile (p16^INK4a^↑, lamin B1↓) (claim)[4]. Vagal afferents relay this altered serotonergic tone to the nucleus tractus solitarius, where it modulates hypothalamic histone acetylation, influencing systemic IGF‑1 and mTOR activity (claim)[6].

3. Feedback loop amplifies systemic decline – Serotonin‑driven changes in gut motility reshape the microbiota, decreasing butyrate producers and further suppressing TPH1 in remaining healthy EC cells, creating a vicious cycle that spreads epigenetic drift to distal tissues (lung, brain, muscle) (claim)[1].

Testable predictions

• Prediction 1: Genetic ablation of senescent EC cells (using a p16‑INK4a‑driven CreERT2 crossed to a DTA reporter) in 24‑month‑old mice will reduce colonic serotonin levels by >40% and normalize SASP cytokine levels within two weeks (claim)[3].

• Prediction 2: EC‑specific senolysis will restore youthful DNA methylation patterns (measured by epigenetic clock CpGs) in intestinal crypts and in distal tissues (liver, hippocampus) as shown by reduced Horvath‑like age acceleration (claim)[5].

• Prediction 3: Treated mice will exhibit improved hallmarks: increased colonic motility, elevated fecal butyrate, reduced circulating IL‑6, enhanced grip strength, and better performance in the Morris water maze versus vehicle‑treated aged controls (claim)[4].

Falsifiability

If EC‑targeted senolysis fails to (a) lower colonic serotonin, (b) revert epigenetic age signatures, or (c) improve at least two distinct hallmarks (e.g., inflammation and frailty) compared with controls, the hypothesis that EC cell senescence is a singular upstream controller of aging is refuted.